近日，欧洲内科肿瘤学会（ESMO）公布了即将召开的2023年ESMO大会上最为重磅的摘要LBAs（Late- Breaking Abstracts）题目及信息，覆盖Presidential Symposium（主席专场）、Proffered Paper Session（优选论文专场）、Mini Oral Session（简短口头摘要专场）。
【肿瘤资讯】特整理2023 ESMO大会泌尿肿瘤领域的重磅LBA标题，与您同鉴！
优选论文专场——泌尿肿瘤，前列腺癌
Proffered Paper session - Genitourinary tumours, prostate
LBA84 - 恩扎卢胺和177 Lu-PSMA-617治疗低风险、转移性、去势抵抗性前列腺癌（mCRPC）：一项随机、II期试验：ENZA-p（ANZUP 1901）
Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): a randomised, phase 2 trial: ENZA-p (ANZUP 1901)
讲者：Louise Emmett (Darlinghurst, Australia)
优选论文专场——泌尿肿瘤，非前列腺癌
Proffered Paper session - Genitourinary tumours, non-prostate
LBA102 - THOR-2队列1：厄达替尼（ERDA）与膀胱内化疗在既往接受卡介苗（BCG）治疗的伴有特定成纤维细胞生长因子受体改变（FGFRALT）的高危非肌层浸润性膀胱癌（HR NMIBC）患者中的结果
THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment
讲者：James W. Catto (Sheffield, United Kingdom)
LBA103 - ICRA：紫杉醇联合Tremelimumab+/-度伐利尤单抗治疗铂类化疗和抗PD-（L）1治疗进展后的转移性尿路上皮癌的疗效
ICRA: efficacy of paclitaxel with tremelimumab +/- durvalumab in metastatic urothelial carcinoma after progression on platinum chemotherapy and anti-PD-(L)1
讲者：Sarah M.H. Einerhand (Amsterdam, Netherlands)
LBA87 - Belzutifan联合卡博替尼治疗晚期透明细胞肾细胞癌（ccRCC）的II期LITESPARK-003研究
Phase 2 LITESPARK-003 Study of Belzutifan in Combination With Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
讲者：Toni K. Choueiri (Boston, United States of America)
LBA88 -在既往接受过治疗的晚期透明细胞肾细胞癌（ccRCC）受试者中比较Belzutifan与依维莫司：随机、开放标签、III期LITESPARK-005研究
Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase 3 LITESPARK-005 study
讲者：Laurence Albiges (Villejuif, Cedex, France)
简短口头报告专场——泌尿肿瘤，前列腺癌Mini oral session - Genitourinary tumours, prostate
LBA85 -尼拉帕利（NIRA）联合醋酸阿比特龙+泼尼松（AAP）作为转移性去势抵抗性前列腺癌（mCRPC）和同源重组修复（HRR）基因改变患者的一线治疗：MAGNITUDE的三年更新和最终分析
Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
讲者：Kim Nguyen N. Chi (Vancouver, Canada)
LBA86 - 雄激素受体通路抑制剂或紫杉烷类药物用于转移性去势抵抗性前列腺癌患者：ProBio中的直接比较，一项随机、结局适应性、生物标志物驱动的平台试验
Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial
讲者：Henrik Grönberg (Stockholm, Sweden)
简短口头报告专场——泌尿肿瘤，非前列腺癌Mini oral session - Genitourinary tumours, non-prostate
LBA104 -TAR-210 厄达替尼（erda）膀胱内给药系统在具有选定FGFR改变的非肌层浸润性膀胱癌（NMIBC）患者中的首次安全性和疗效结果
First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
讲者：Anotni Vilaseca (Barcelona, Spain)
LBA105 - SunRISe-1研究结果：卡介苗（BCG）无反应高风险非肌肉浸润性膀胱癌（HR NMIBC）患者接受TAR-200单药治疗
Results From SunRISe-1 in Patients (Pts) With Bacillus Calmette–Guérin (BCG)-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer (HR NMIBC) Receiving TAR-200 Monotherapy
讲者：Andrea Necchi (Milan, Italy)
优选论文专场——主席专场
Proffered Paper session - Presidential
LBA6 - EV-302/KEYNOTE-A39：Enfortumab Vedotin联合Pembrolizumab（EV+P）与化疗治疗既往未经治疗的局部晚期转移性尿路上皮癌（la/mUC）的开放标签、随机化、III期研究
EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC)
讲者：Thomas B. Powles (London, United Kingdom)
LBA13 -[177 Lu]Lu-PSMA-617在未接受过紫杉烷治疗的转移性去势抵抗性前列腺癌患者中的3期试验（PSMAfore）
Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)Speakers：Oliver Sartor (Rochester, United States of America)
讲者：Oliver Sartor (Rochester, United States of America)
https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session/calendar
排版编辑：肿瘤资讯-CY
苏公网安备 32059002004080号
